“The company recently received an approval number from the US Food and Drug Administration (FDA) for the release of desvenlafaxine sustained-release tablets.” Chen Liying, financial director of Yichang Renfu Pharmacy Co., Ltd., told the reporter the other day and said it means that Renfu can produce and sell the drug in the US market.

　　The tablets are used to treat major depression in adults. To research and develop the drug, Renfu has invested 9 million yuan and submitted an ANDA application of it last year.

　　"This is the fourth US FDA approval number the company has received this year." Chen Liying said that the successive tax incentives have encouraged the company to invest more on its R&D innovation. In the past two years, Renfu's R&D expenses together with extra deductions have reached 78.03 million yuan and 93.27 million yuan respectively, with a reduction of its corporate income tax of 11.7 million yuan and 13.99 million yuan each. After being recognized as a high-tech enterprise, its corporate income tax has been further reduced by nearly 65 million yuan every year, along with a series of true benefits such as the reduction of VAT rate, which makes the company's cash flow more affluent. In addition, the enterprise also enjoys a tax credit for a certain percentage in the purchase of equipment used in environmental protection, energy conservation, water conservation, and safe production.

　　Chen Liying said that the company will vigorously promote its transformation and upgrading next, and develop world-class new drugs, continuing to lead the market segment and actively advancing the preparation for the drug to be put in the US market. (Reporter: Gao Shengnan; Correspondent: Yang Kai, Wu Zhu)